Treatment of Localized Dedifferentiated Liposarcoma in the Retroperitoneum
Dedifferentiated liposarcoma arising in the retroperitoneum (RP DDLPS) presents distinct surgical and oncologic challenges. The retroperitoneal location means the tumor is often large at diagnosis, frequently abutting or involving adjacent abdominal organs. Management of this localized disease requires careful multidisciplinary planning centered on achieving complete resection.
Clinical Scenario
Localized dedifferentiated liposarcoma located in the retroperitoneum. In this anatomical site, the tumor typically arises from the perinephric fat and is large, abutting or involving multiple intra-abdominal organs — most commonly the kidney and colon. Complete en bloc resection is the cornerstone of management for this disease.
Treatment Approach (Partial Overview)
The primary treatment strategy centers on surgical resection — specifically an en bloc macroscopically complete resection, which often requires removal of adjacent viscera to achieve clear margins. Beyond surgery, there are defined considerations regarding radiation therapy and perioperative systemic therapy, each with specific roles and conditions under which they may be employed.
The full structured protocol — including the complete resection strategy, radiation guidance, and perioperative systemic therapy recommendations — is available via the link below.
References
DOI: 10.1016/j.ctrv.2024.102846
- A complete en bloc resection is the cornerstone of management for RP DDLPS.
- In the RP, DDLPS typically arises from the perinephric fat and is large, abutting, or involving multiple intra-abdominal organs, most commonly the kidney and colon.
- To achieve complete removal, a multi-visceral resection is often necessary, aiming for a macroscopically complete resection.
- Macroscopic complete resection is the standard of care for RP sarcoma and routine treatment with RT is not recommended for DDLPS of RP (or any RP sarcoma).
- For RP sarcoma, if RT is recommended after multidisciplinary discussion and shared decision making with the patient, the same preoperative dose of 50 Gy delivered over 5 weeks is recommended.
- If perioperative chemotherapy is being considered for RP DDLPS, neoadjuvant chemotherapy is preferred.
View source ↗